Capital Fund Management S.A. Has $21.13 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Capital Fund Management S.A. lessened its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 14.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 173,745 shares of the biotechnology company's stock after selling 30,401 shares during the quarter. Capital Fund Management S.A. owned approximately 0.18% of Sarepta Therapeutics worth $21,126,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in SRPT. Louisiana State Employees Retirement System lifted its position in shares of Sarepta Therapeutics by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company's stock valued at $3,222,000 after buying an additional 100 shares during the last quarter. Manchester Capital Management LLC lifted its holdings in Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 110 shares during the last quarter. UMB Bank n.a. boosted its position in Sarepta Therapeutics by 36.0% during the fourth quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company's stock worth $63,000 after purchasing an additional 138 shares during the period. CIBC Asset Management Inc increased its holdings in shares of Sarepta Therapeutics by 5.1% in the fourth quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company's stock valued at $347,000 after purchasing an additional 139 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its position in shares of Sarepta Therapeutics by 5.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company's stock valued at $352,000 after purchasing an additional 145 shares during the period. 86.68% of the stock is owned by institutional investors.

Remove Ads

Sarepta Therapeutics Trading Down 0.4 %

NASDAQ:SRPT traded down $0.21 during trading hours on Tuesday, hitting $54.42. 2,213,741 shares of the company were exchanged, compared to its average volume of 1,395,798. The company has a fifty day simple moving average of $86.82 and a 200 day simple moving average of $109.61. Sarepta Therapeutics, Inc. has a one year low of $48.01 and a one year high of $173.25. The stock has a market capitalization of $5.28 billion, a price-to-earnings ratio of 43.54 and a beta of 0.93. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Insider Buying and Selling

In other news, Director Claude Nicaise sold 2,491 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now directly owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 7.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages recently commented on SRPT. Royal Bank of Canada lowered shares of Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and decreased their price target for the company from $161.00 to $87.00 in a research note on Monday, March 31st. Needham & Company LLC lowered their target price on Sarepta Therapeutics from $202.00 to $183.00 and set a "buy" rating on the stock in a research note on Thursday, April 3rd. Wells Fargo & Company started coverage on Sarepta Therapeutics in a report on Friday. They issued an "overweight" rating and a $115.00 price objective on the stock. Scotiabank dropped their target price on Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a report on Thursday, March 20th. Finally, HC Wainwright upgraded shares of Sarepta Therapeutics from a "sell" rating to a "neutral" rating and set a $75.00 price target on the stock in a research note on Wednesday, April 2nd. Six research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $161.83.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.